Previous studies have demonstrated that the positive expression of PD-L1 on tumor cells was a significant biomarker to predict favorable outcomes of anti-PD-1 treatment.[2,4] However, the role of PD-L1 expression as a predictive biomarker of the response to nivolumab treatment remains controversial.[6] Although some patients fail to respond to nivolumab treatment despite positive PD-L1 expression, others benefit clinically regardless of negative PD-L1 expression. Here, CD274 is linked to neoplasm.